US 12,202,828 B2
Bicyclic heterocycle compounds and their uses in therapy
Gianni Chessari, Cambridge (GB); Christopher Norbert Johnson, Saffron Walden (GB); Steven Howard, Cambridge (GB); James Edward Harvey Day, Cambridge (GB); Ildiko Maria Buck, London (GB); Charlotte Mary Griffiths-Jones, Cambridge (GB); Gordon Saxty, Zagreb (HR); Emiliano Tamanini, Cambridge (GB); and Nicola Elizabeth Wilsher, Newmarket (GB)
Assigned to ASTEX THERAPEUTICS LIMITED, Cambridge (GB)
Filed by ASTEX THERAPEUTICS LIMITED, Cambridge (GB)
Filed on Dec. 21, 2022, as Appl. No. 18/069,571.
Application 17/643,083 is a division of application No. 16/795,117, filed on Feb. 19, 2020, granted, now 11,225,476, issued on Jan. 18, 2022.
Application 16/795,117 is a division of application No. 15/675,052, filed on Aug. 11, 2017, granted, now 10,618,895, issued on Apr. 14, 2020.
Application 18/069,571 is a continuation of application No. 17/643,083, filed on Dec. 7, 2021, granted, now 11,643,410.
Application 15/675,052 is a continuation of application No. 15/105,360, granted, now 9,783,538, issued on Oct. 10, 2017, previously published as PCT/GB2014/053778, filed on Dec. 19, 2014.
Claims priority of application No. 1322755 (GB), filed on Dec. 20, 2013; and application No. 1406986 (GB), filed on Apr. 17, 2014.
Prior Publication US 2023/0227450 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/5377 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/5377 (2013.01)] 48 Claims
 
1. A protected form of a compound of formula (I), wherein formula (I) is:

OG Complex Work Unit Chemistry
or a tautomeric or a stereochemically isomeric form, a pharmaceutically acceptable salt or a solvate thereof,
wherein
X is CR4, N or NR3;
wherein
when X is CR4, then U represents nitrogen and R6 represents oxo; or
when X is N, then U represents carbon and R6 represents hydroxymethyl or —CH(ORx)CH2OR2; or
when X is NR3, then U represents carbon and R6 represents oxo;
dashed bond (custom character) represents a single or double bond wherein at least two of said dashed bonds represent a double bond;
R3 represents hydrogen, methyl or —NH2;
R4 represents hydrogen, methyl, hydroxymethyl, —NH2 or fluorine;
R5 represents unsubstituted n-butyl or benzyl substituted on the phenyl group by one or two fluorines;
Rx and Rz independently represent hydrogen or methyl; and
R1 and R2 independently represent hydrogen or methyl.